Comment on the draft interim update to atopic dermatitis care guidelines for systemic JAK inhibitors and biologics
The AAD is seeking member comments on a draft interim update to guidelines of care for atopic dermatitis with systemic JAK inhibitors and biologics. This interim update provides evidence-based recommendations of AD treatments by following the GRADE methodology, with recommendations formed by a guideline work group that included experts in AD management from varied clinical settings and methodologists.
The comment period is open to all AAD members and comments are being accepted through Aug. 3, 2026. Feedback received will be provided to the guideline development work group for review.
If you have questions, please email Irum Hameeduddin at ihameeduddin@aad.org.
Draft guideline and supplement
There are three PDFs available for review.
Download the draft guideline itself.
Access the supplement to the guideline.
Access the recommendations to the supplement.
